Results highlighted in two oral presentations at the American Society of Hematology Annual Meeting In a second oral presentation, results from a sub-group analysis of the primary study were ...

In contrast, no added benefit proven in initial treatment of patients with BMI up to 28 kg/m2 and in long-term prevention Institute for Quality and Efficiency in Health Care Apixaban (trade name ...

Bristol-Myers Squibb Company, a global biopharmaceutical company, and Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has ...

Thromboembol in blood vessel. Clot formation, 3D illustration Researchers sought to compare oral apixaban and subcutaneous dalteparin for treating patients with cancer-related venous thromboembolism.

ASH: Extended apixaban cuts recurrent VTE risk Taking apixaban for an additional year after standard treatment reduced recurrent venous thromboembolism without increasing major bleeding. HealthDay ...

Recent guidelines recommend consideration of the use of oral edoxaban or rivaroxaban for the treatment of venous thromboembolism in patients with cancer. However, the benefit of these oral agents is ...

In patients with active cancer who have been hospitalized for a venous thromboembolism (VTE) event, rivaroxaban (Xarelto; Bayer/Janssen) is as effective as apixaban (Eliquis; Bristol-Myers Squibb) in ...

Please provide your email address to receive an email when new articles are posted on . Treatment of venous thromboembolism with oral apixaban was noninferior to subcutaneous dalteparin, without ...

The disadvantages of dabigatran include a higher cost compared with warfarin, the need for twice-daily dosing, and a slightly increased risk for gastrointestinal bleeding (6.1% with dabigatran vs 4% ...

Hospital and advocacy group opposition to state public options could foretell trouble for national single-payer efforts; electronic health records (EHRs) present new opportunities for fraud; the FDA ...

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--The Bristol-Myers Squibb-Pfizer Alliance today announced results from retrospective real-world data analyses reporting outcomes on the safety and ...